Results 201 to 210 of about 31,391,825 (411)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Personalized Surgical Tactics for an Adult Patient with Mitral Insufficiency and Dextrocardia with Situs Inversus Totalis. [PDF]

Braz J Cardiovasc Surg
Kozlov BN, Petlin KA, Lelik EV, Afanasieva NL, Arsenyeva YA, Chernykh YN, Kim EB.   +6 more
europepmc   +1 more source

Dexmedetomidine in Cardiac Surgery Patients Who Fail Extubation and Present with a Delirium State

, 2011
Nihan Yapící, Türkan Çoruh, Tamer Kehlіbar, Fikri Yapıcı, Arif Tarhan, Yeşim Can, Azmi Özler, Zuhal Aykaç   +7 more
openalex   +1 more source

Optimizing Crisis Resource Management to Improve Patient Safety and Team Performance - A handbook for acute care health professionals [PDF]

, 2017
Laura V. Duggan
openalex   +1 more source

SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer.

The Oncologist, 2000
W. Baile, R. Buckman, R. Lenzi, G. Glober, E. Beale, A. Kudelka   +5 more
semanticscholar   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Study on nutritional status and incidence of sarcopenia in elderly patients with chronic heart failure. [PDF]

Asia Pac J Clin Nutr
Song S, Du H, Lu X, Luo B, Li Z.
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Zolpidem Withdrawal Delirium Developed as Severe Psychiatric and Physical Symptoms in a Patient With a History of Ovarian Cancer: A Case Report and Literature Review. [PDF]

Neuropsychopharmacol Rep
Yamaguchi J, Sadahiro R, Wada S, Nishikawa E, Terada T, Nakahara R, Matsuoka H.   +6 more
europepmc   +1 more source

Superior Benefit of Aggressive Lipid-Lowering Therapy for High- Risk Patients Using Statins: the SUBARU Study -More Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy than with Atorvastatin Therapy

, 2008
Masahiko Kurabayashi, Tsutomu Yamazaki, SUBARU Study Group   +2 more
openalex   +2 more sources